- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.
Avaglim : EPAR - Summary for the public
English (EN) (511.34 KB - PDF)
български (BG) (676.95 KB - PDF)
español (ES) (574.56 KB - PDF)
čeština (CS) (639.66 KB - PDF)
dansk (DA) (577.22 KB - PDF)
Deutsch (DE) (580.29 KB - PDF)
eesti keel (ET) (575.67 KB - PDF)
ελληνικά (EL) (688.24 KB - PDF)
français (FR) (578.92 KB - PDF)
italiano (IT) (579.68 KB - PDF)
latviešu valoda (LV) (646.64 KB - PDF)
lietuvių kalba (LT) (606.52 KB - PDF)
magyar (HU) (629.47 KB - PDF)
Malti (MT) (577.48 KB - PDF)
Nederlands (NL) (574.86 KB - PDF)
polski (PL) (639.54 KB - PDF)
português (PT) (574.95 KB - PDF)
română (RO) (607.15 KB - PDF)
slovenčina (SK) (635.29 KB - PDF)
slovenščina (SL) (630.33 KB - PDF)
Suomi (FI) (576.98 KB - PDF)
svenska (SV) (575.64 KB - PDF)
Product information
Avaglim : EPAR - Product Information
English (EN) (1.12 MB - PDF)
български (BG) (2.77 MB - PDF)
español (ES) (1.33 MB - PDF)
čeština (CS) (1.83 MB - PDF)
dansk (DA) (1.27 MB - PDF)
Deutsch (DE) (1.23 MB - PDF)
eesti keel (ET) (1.12 MB - PDF)
ελληνικά (EL) (2.57 MB - PDF)
français (FR) (1.19 MB - PDF)
italiano (IT) (1.33 MB - PDF)
latviešu valoda (LV) (2.07 MB - PDF)
lietuvių kalba (LT) (1.57 MB - PDF)
magyar (HU) (1.75 MB - PDF)
Malti (MT) (1.84 MB - PDF)
Nederlands (NL) (2.12 MB - PDF)
polski (PL) (2.02 MB - PDF)
português (PT) (1.39 MB - PDF)
română (RO) (1.51 MB - PDF)
slovenčina (SK) (1.98 MB - PDF)
slovenščina (SL) (1.88 MB - PDF)
Suomi (FI) (1.15 MB - PDF)
svenska (SV) (1.28 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Avaglim : EPAR - All Authorised presentations
English (EN) (436.09 KB - PDF)
български (BG) (522.48 KB - PDF)
español (ES) (436.31 KB - PDF)
čeština (CS) (475.2 KB - PDF)
dansk (DA) (436.62 KB - PDF)
Deutsch (DE) (435.54 KB - PDF)
eesti keel (ET) (436.51 KB - PDF)
ελληνικά (EL) (518.76 KB - PDF)
français (FR) (436.15 KB - PDF)
italiano (IT) (435.76 KB - PDF)
latviešu valoda (LV) (511.76 KB - PDF)
lietuvių kalba (LT) (504.68 KB - PDF)
magyar (HU) (550.99 KB - PDF)
Nederlands (NL) (429.54 KB - PDF)
polski (PL) (476.63 KB - PDF)
português (PT) (436.67 KB - PDF)
română (RO) (498.13 KB - PDF)
slovenčina (SK) (474.6 KB - PDF)
slovenščina (SL) (473.16 KB - PDF)
Suomi (FI) (435.82 KB - PDF)
svenska (SV) (436.71 KB - PDF)
Product details
- Name of medicine
- Avaglim
- Active substance
- rosiglitazone
- glimepiride
- International non-proprietary name (INN) or common name
- rosiglitazone
- glimepiride
- Therapeutic area (MeSH)
- Diabetes Mellitus, Type 2
- Anatomical therapeutic chemical (ATC) code
- A10BD04
Pharmacotherapeutic group
Drugs used in diabetesTherapeutic indication
AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.
Authorisation details
- EMA product number
- EMEA/H/C/000675
- Marketing authorisation holder
- SmithKline Beecham Ltd
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom - Marketing authorisation issued
- 27/06/2006
- Revision
- 11
Assessment history
Avaglim : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (442.61 KB - PDF)
Avaglim-H-C-675-A-20-29: EPAR - Assessment Report
English (EN) (1.29 MB - PDF)
Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Avaglim on 24 January 2008
English (EN) (33.85 KB - PDF)